By September 15, 2026: Billing team must identify all affected specialty medications (Dupixent, Opdivo, Yervoy, Tecentriq, Imfinzi, Yescarta, Enhertu, Qalsody, Vyjuvek, Hepcludex, Decnupaz, Lumvoa, Trutakna, and others listed) and cross-reference current claim submission processes. Access Anthem's Clinical Criteria page to retrieve full policy details for CC-0029, CC-0031, CC-0032, CC-0043, CC-0057, CC-0061, CC-0077, CC-0099, CC-0112, CC-0119, CC-0121, CC-0125, CC-0128, CC-0130, CC-0151, CC-0158, CC-0163, CC-0218, CC-0237, CC-0243, CC-0258, CC-0276, CC-0279, CC-0281, CC-0303, CC-0304, CC-0305, and CC-0306. Providers must review the revised medical necessity criteria and update prior authorization processes accordingly. Billing team must monitor for separate authorization requirement notices from Anthem. Update internal clinical criteria tracking spreadsheet with new effective dates. Establish escalation process for claims submitted 9/15-9/30 that may be affected by the transition. Failure to align with revised criteria may result in claim denials or delays for medical drug benefit claims.